Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...

GlobalData has suggested that Ohtuvayre could have a transformative role to play in the management of COPD patients who are prone to exacerbations, sudden flare-ups in symptoms that signal the ...

Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

Discover the top 19 most notable drugs approved by the FDA in 2024, including Dupixent for COPD and FluMist for self-administration. See the full list here.

Consensus for Q4 revenue is $12.94M. Expects to report cash and cash equivalents at December 31, 2024, of $400M vs. $271.8M a year ago. “2024 ...

4. Verona’s Ohtuvayre (ensifentrine) for COPD Just as Verona Pharma secured the FDA nod to market inhalable COPD drug Ohtuvayre in June, its commercial prospects seemed to improve markedly. While ...

Truist raised the firm’s price target on Verona Pharma (VRNA) to $57 from $44 and keeps a Buy rating on the shares. The firm cites the ...